Reference miRNAs for miRNAome Analysis of Urothelial Carcinomas
Nadine Ratert(Charité - Universitätsmedizin Berlin), Klaus Jung(University of Veterinary Medicine Hannover, Foundation), Ina Wagner(Max Planck Institute for Infection Biology), Ergin Kilic(Istanbul Technical University), Hellmuth‐Alexander Meyer(Charité - Universitätsmedizin Berlin), Monika Jung(Charité - Universitätsmedizin Berlin), Kurt Miller(Charité - Universitätsmedizin Berlin), Hans‐Joachim Mollenkopf(Max Planck Institute for Infection Biology), Steffen Weikert(St. Hedwig-Krankenhaus), Andreas Erbersdobler(Universitätsmedizin Rostock)
Cited by 77
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma
|International Journal of Cancer|2009|613